VEGFA and gastric cancer: In 2011, the Avastin in Gastric Cancer (AVAGAST) trial was the first clinical trial to elucidate the superior efficacy of adding bevacizumab (Bev), a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF-A), in combination with chemotherapy for patients with AGC.